[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
The Pediatric Forum
Oct 2012

Methodological Concerns Regarding Cost-effectiveness Analysis of Palivizumab in Florida Medicaid

Author Affiliations

Author Affiliations: Health Outcomes and Pharmacoeconomics (Drs Mahadevia and Masaquel) and Medical Affairs (Dr Makari), MedImmune LLC, Gaithersburg, Maryland.

Arch Pediatr Adolesc Med. 2012;166(10):968-970. doi:10.1001/archpediatrics.2012.1591

Hampp and colleagues1 present an economic analysis of palivizumab prophylaxis during the 2004-2005 respiratory syncytial virus (RSV) season in Florida using Medicaid claims data and assert that palivizumab prophylaxis is not cost-effective compared with no prophylaxis. Several important variables were not considered, which limits the scope of the investigators' conclusions. In addition, their analysis seemed to deviate from guidelines established by the US Panel on Cost-effectiveness in Health and Medicine.2

First Page Preview View Large
First page PDF preview
First page PDF preview